Literature DB >> 6973570

Biosynthesis and maturation of HLA-DR antigens in vivo.

M J Owen, A M Kissonerghis, H F Lodish, M J Crumpton.   

Abstract

The biosynthesis of the HLA-DR antigens was studied in the B lymphoblastoid cell line BRI 8. Three chains, of molecular weights 33,000 (alpha), 31,000 (p31), and 26,000 (beta) were detected intracellularly in pulse-labeled cells by immunoprecipitation with anti-(HLA-DR) sera. The alpha and beta chains were inserted asymmetrically into the rough endoplasmic reticulum as transmembrane polypeptides with the majority of the polypeptide chains oriented in the lumen. At this stage, both chains carried "high mannose" oligosaccharide units which were processed to the complex form during subsequent intracellular transport to the cell surface. The Mr = 31,000 polypeptide was also glycosylated but was structurally distinct from the alpha chain and was probably oriented differently in the lipid bilayer, with a much greater proportion of its polypeptide chain exposed in the cytoplasm. It ws not, therefore, a precursor of the alpha chain. The mature HLA-DR antigens at the plasma membrane comprised polypeptides of Mr = 34,000 and 28,000. These chains corresponded to the processed alpha and beta chains. Although the Mr = 31,000 component was only detected intracellularly, it was not ruled out that some or all of it may have been processed and exposed on the cell surface with an apparent molecular weight indistinguishable from that of the alpha chain.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6973570

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.

Authors:  Toine ten Broeke; Richard Wubbolts; Willem Stoorvogel
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

Review 2.  Protein sorting within the MHC class II antigen-processing pathway.

Authors:  M S Marks
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

3.  Nonimmune human cells can express MHC class II antigens in the absence of invariant chain--an immunohistological study on normal and chronically inflamed small intestine.

Authors:  F Momburg; K Koretz; A Von Herbay; P Möller
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

4.  Sequence of rat interleukin 2 and anomalous binding of a mouse interleukin 2 cDNA probe to rat MHC class II-associated invariant chain mRNA.

Authors:  A J McKnight; D W Mason; A N Barclay
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

5.  Intracellular class II HLA antigens are accessible to transferrin-neuraminidase conjugates internalized by receptor-mediated endocytosis.

Authors:  P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  Sheep MHC class II molecules. I. Immunochemical characterization.

Authors:  N K Puri; M D Gorrell; M R Brandon
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

Review 7.  In search of a function for the invariant chain associated with Ia antigens.

Authors:  E O Long
Journal:  Surv Immunol Res       Date:  1985

8.  Role for intracellular proteases in the processing and transport of class II HLA antigens.

Authors:  J S Blum; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts.

Authors:  T Collins; A J Korman; C T Wake; J M Boss; D J Kappes; W Fiers; K A Ault; M A Gimbrone; J L Strominger; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens.

Authors:  E O Long; M Strubin; C T Wake; N Gross; S Carrel; P Goodfellow; R S Accolla; B Mach
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.